In a sec­ond big set­back for Covid-19 an­ti­body treat­ment hopes, Re­gen­eron halts en­roll­ment for more se­vere pa­tients

Re­gen­eron has just de­liv­ered more bad news for the hope that neu­tral­iz­ing an­ti­bod­ies could be used to treat pa­tients with more se­vere forms of Covid-19.

The New York biotech said to­day that an in­de­pen­dent mon­i­tor­ing com­mit­tee rec­om­mend­ed halt­ing en­roll­ment of pa­tients who need high-flow oxy­gen or me­chan­i­cal ven­ti­la­tion in one of the tri­als on their an­ti­body cock­tail, af­ter find­ing “a po­ten­tial safe­ty sig­nal” and “an un­fa­vor­able risk/ben­e­fit pro­file.” The news comes a week af­ter the NIH scrapped a tri­al of Eli Lil­ly’s Covid-19 an­ti­body af­ter find­ing it was hav­ing lit­tle ef­fect on an ini­tial co­hort of hos­pi­tal­ized pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER